Adaptimmune Therapeutics (ADAP) FDA Announcement summary

Introduction and purpose

• Tecelra (afamitresgene autoleucel) received accelerated FDA approval as the first engineered cell therapy for a solid tumor, specifically for adults with advanced MAGE-A4+ synovial sarcoma who have received prior chemotherapy and meet specific HLA criteria.

• The approval marks a significant milestone for cell therapy, offering a new treatment option for a rare cancer affecting young and middle-aged adults with limited alternatives.

• Emphasized commitment to redefining cancer treatment through innovative cell therapies, focusing on high unmet needs in solid tumors.

Details of approval or decision

• Tecelra is the first new treatment for synovial sarcoma in over a decade, available at a list price of $727,000.

• FDA approval is based on overall response rate and duration of response from the pivotal SPEARHEAD-1 trial; continued approval may depend on confirmatory trials.

• Companion diagnostics for MAGE-A4 and HLA testing from Agilent and Thermo Fisher were also approved, enabling broad patient access.

• Tecelra is indicated for adults with unresectable or metastatic synovial sarcoma, HLA-A02:01P, -A02:02P, -A02:03P, or -A02:06P positive, and MAGE-A4 antigen expression.

Impact on industry and stakeholders

• Tecelra's approval is expected to redefine synovial sarcoma treatment and expand the reach of cell therapies into solid tumors, establishing a foundation for a sarcoma franchise.

• Adaptimmune is onboarding 6–10 treatment centers initially, aiming for about 30 authorized centers within two years to ensure national access.

• AdaptimmuneAssist support program launched to aid patients, caregivers, and providers with access, navigation, and financial support.

• Positive engagement with payers and established reimbursement pathways support access for eligible patients.